<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188603</url>
  </required_header>
  <id_info>
    <org_study_id>511.146</org_study_id>
    <nct_id>NCT01188603</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)</brief_title>
  <official_title>Evaluation of Single Dose and Steady State Pharmacokinetics of Flibanserin Postmenopausal Women With Hypoactive Sexual Desire Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sprout Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sprout Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial examines the way flibanserin is metabolized in postmenopausal women with
      Hypoactive Sexual Desire Disorder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flibanserin: Area Under the Curve; AUC_0-∞</measure>
    <time_frame>8 days</time_frame>
    <description>Geometric mean of the AUC_0-∞ of Flibanserin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flibanserin: AUC τ,ss</measure>
    <time_frame>8 days</time_frame>
    <description>Geometric mean of the AUC τ,ss of Flibanserin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flibanserin: Cmax (Peak Concentration)</measure>
    <time_frame>8 days</time_frame>
    <description>Geometric mean of the Cmax of Flibanserin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flibanserin: Cmax,ss</measure>
    <time_frame>8 days</time_frame>
    <description>Geometric mean of the Cmax,ss of Flibanserin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flibanserin: Tmax,ss</measure>
    <time_frame>8 days</time_frame>
    <description>Median of the tmax,ss of Flibanserin</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Sexual Dysfunctions, Psychological</condition>
  <arm_group>
    <arm_group_label>flibanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flibanserin 100 mg dose every evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>flibanserin 100 mg dose every evening</intervention_name>
    <description>all subjects receive flibanserin</description>
    <arm_group_label>flibanserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients must be in a stable, monogamous heterosexual relationship for at least one
             year.

          2. Patients must have a primary diagnosis of Hypoactive Sexual Desire Disorder for at
             least six months.

          3. Patients must be naturally postmenopausal women of any age with at least one ovary.

          4. Patients may participate whether or not they are currently taking systemic hormone
             therapy provided the therapy was not prescribed for treatment of low sexual desire.
             Hormone therapy must be at a stable dose for at least six months.

        Exclusion criteria:

          1. Patients with a history of drug dependence or abuse within the past twelve months.

          2. Patients who have been previously treated with flibanserin.

          3. Patients who have sexual dysfunctions other than Hypoactive Sexual Desire Disorder,
             such as: Sexual Aversion Disorder, Substance-Induced Sexual Dysfunction, Dyspareunia,
             Vaginismus, Gender Identity Disorder,Paraphilia, or Sexual Dysfunction due to a
             general medical condition.

          4. Patients who indicate that their sexual partner has inadequately treated organic or
             psychosexual dysfunction that could interfere with a patients response to treatment.

          5. Patients whose sexual function was impaired, in the investigators opinion, by
             abdominal or vaginal hysterectomy, oophorectomy or any other pelvic, vaginal, or
             urologic surgery.

          6. Patients with pelvic pain, pelvic inflammatory disease, endometriosis, urinary tract
             or vaginal infection/vaginitis, cervicitis, interstitial cystitis, vulvodynia,
             symptomatic vaginal atrophy or any other gynecological pathology requiring further
             evaluation.

          7. Patients with a history of unexplained vaginal bleeding within the past twelve months.

          8. Patients with a history of Major Depressive Disorder within six months prior to
             Screening; ; active suicidal ideation with intent in the past ten years or suicidal
             behavior at any time.

          9. Patients with a history of any other psychiatric disorder that could impact sexual
             function, increase risks to patient safety, or impair patient compliance. Such
             disorders include but are not limited to bipolar disorder, psychotic disorders, severe
             anxiety, eating disorders, and antisocial personality disorders.

         10. Clinically significant electrocardiogram abnormalities at Screening.

         11. Patients with a history of dementia or other neurodegenerative disease; organic brain
             disease; stroke; transient ischemic attacks; multiple sclerosis; spinal cord injury;
             brain surgery; significant brain trauma; peripheral neuropathy; and epilepsy.

         12. Patients with ongoing hepatic impairment (cirrhosis, hepatic tumor, or other hepatic
             disease); peptic ulcer within six months prior to Screening; elevated liver enzymes ;
             inflammatory bowel disease; gastrointestinal bleeding within two months prior to
             Screening; Patients who have had bariatric surgery for obesity.

         13. Patients with a history of angina; atherosclerotic cardiovascular disease; congestive
             heart failure; cardiomyopathy; symptomatic cardiac valve disease; arrhythmia;
             hypertension.

         14. Patients with a history of renal failure; known history of chronic glomerulonephritis.

         15. Patients with a history of chronic obstructive pulmonary disease, chronic bronchitis,
             or asthma not well controlled with medication taken twice daily or less.

         16. Patients with a history of gonadotrophic hormone disorders or uncontrolled diabetes
             mellitus.

         17. Uncorrected hypothyroidism or hyperthyroidism.

         18. Patients with a history of uncontrolled glaucoma.

         19. Patients with known Human Immunodeficiency Virus infection, Acquired Immunodeficiency
             Syndrome, other clinically significant immunological disorders or auto-immune
             disorders such as lupus or scleroderma.

         20. Patients with a history of any cancer within the past ten years, other than
             non-invasive, previously resected basal cell carcinoma of the skin.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sprout Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Sprout Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>511.146.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.146.01005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.146.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>511.146.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2010</study_first_submitted>
  <study_first_submitted_qc>August 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <results_first_submitted>May 4, 2011</results_first_submitted>
  <results_first_submitted_qc>March 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2012</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Flibanserin</title>
          <description>100mg Flibanserin administered orally once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flibanserin</title>
          <description>100mg Flibanserin administered orally once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Patients</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.25" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flibanserin: Area Under the Curve; AUC_0-∞</title>
        <description>Geometric mean of the AUC_0-∞ of Flibanserin</description>
        <time_frame>8 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin</title>
            <description>100mg Flibanserin administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flibanserin: Area Under the Curve; AUC_0-∞</title>
          <description>Geometric mean of the AUC_0-∞ of Flibanserin</description>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2570" spread="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flibanserin: AUC τ,ss</title>
        <description>Geometric mean of the AUC τ,ss of Flibanserin</description>
        <time_frame>8 days</time_frame>
        <population>All patients with values for the area under the concentration-time curve of the analyte in plasma over a dosing interval τ at steady state (AUC τ,ss)</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin</title>
            <description>100mg Flibanserin administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flibanserin: AUC τ,ss</title>
          <description>Geometric mean of the AUC τ,ss of Flibanserin</description>
          <population>All patients with values for the area under the concentration-time curve of the analyte in plasma over a dosing interval τ at steady state (AUC τ,ss)</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3000" spread="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flibanserin: Cmax (Peak Concentration)</title>
        <description>Geometric mean of the Cmax of Flibanserin</description>
        <time_frame>8 days</time_frame>
        <population>All patients with values for the maximum concentration of Flibanserin in plasma after single dose (Cmax)</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin</title>
            <description>100mg Flibanserin administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flibanserin: Cmax (Peak Concentration)</title>
          <description>Geometric mean of the Cmax of Flibanserin</description>
          <population>All patients with values for the maximum concentration of Flibanserin in plasma after single dose (Cmax)</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="56.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flibanserin: Cmax,ss</title>
        <description>Geometric mean of the Cmax,ss of Flibanserin</description>
        <time_frame>8 days</time_frame>
        <population>All patients with values for the maximum concentration of Flibanserin in plasma after single dose at steady state (Cmax,ss)</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin</title>
            <description>100mg Flibanserin administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flibanserin: Cmax,ss</title>
          <description>Geometric mean of the Cmax,ss of Flibanserin</description>
          <population>All patients with values for the maximum concentration of Flibanserin in plasma after single dose at steady state (Cmax,ss)</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406" spread="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flibanserin: Tmax,ss</title>
        <description>Median of the tmax,ss of Flibanserin</description>
        <time_frame>8 days</time_frame>
        <population>All patients with values for the time from dosing to the maximum measured concentration of flibanserin in plasma after single dose at steady state (tmax,ss)</population>
        <group_list>
          <group group_id="O1">
            <title>Flibanserin</title>
            <description>100mg Flibanserin administered orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Flibanserin: Tmax,ss</title>
          <description>Median of the tmax,ss of Flibanserin</description>
          <population>All patients with values for the time from dosing to the maximum measured concentration of flibanserin in plasma after single dose at steady state (tmax,ss)</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="0.500;3.00" lower_limit="0.500" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Flibanserin</title>
          <description>100mg Flibanserin administered orally once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Sprout Pharmaceuticals publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sprout Pharmaceuticals</name_or_title>
      <organization>Sprout Pharmaceuticals</organization>
      <phone>1-919-882-0850</phone>
      <email>clinicaltrials@sproutpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

